Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australia’s Biota, GSK Settle Dispute Over Relenza Promotion

This article was originally published in PharmAsia News

Executive Summary

Biota Holdings of Australia and GlaxoSmithKline have reached a $19 million settlement of a dispute over GSK's method of promoting the Australian firm's Relenza (zanamivir) flu drug. Biota had licensed the drug to GSK for global marketing in 2000, but later accused the U.K. firm of failing to promote it properly. Biota sued GSK for $683 million, but settled for less based on advice a trial would be delayed for a long time at greater cost and risk to Biota. Biota said the two firms would resume their cooperation in promoting the drug. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts